Table 3.
Two-, three-, and five-year survival for black and matched white colon cancer patients by stage
| Black Patients | Matched White Patients
|
|||||
|---|---|---|---|---|---|---|
| Treatment-Match | Presentation-Match | Demographic-Match | ||||
| Stage I | ||||||
| 2-yr survival, % (95% CI) | 84.3 (82.3–86.1) | 85.4 (83.4–87.1) | 86.8 (84.9–88.4) | 88.8 (87.1–90.3) | ||
| Survival difference, % | 1.1* | 1.4 (31.1%)† | 2.5* | 2.0 (44.4%)# | 4.5* | |
| P value | .43 | .062 | .0004 | |||
| 3-yr survival, % (95% CI) | 79.0 (76.8–81.0) | 81.0 (78.9–83.0) | 82.0 (79.9–83.9) | 84.8 (82.9–86.6) | ||
| Survival difference, % | 2.0* | 1.0 (17.2%)† | 3.0* | 2.8 (48.3%)# | 5.8* | |
| P value | .18 | .046 | <.0001 | |||
| 5-yr survival, % (95% CI) | 69.0 (66.5–71.5) | 73.2 (70.8–75.5) | 73.7 (71.3–76.0) | 76.3 (74.0–78.5) | ||
| Survival difference, % | 4.2* | 0.5 (6.8%)† | 4.7* | 2.6 (35.6%)# | 7.3* | |
| P value | .017 | .007 | <.0001 | |||
| Cox HR (95% CI) | 1 (reference) | 0.85 (0.74–0.97) | 0.82 (0.71–0.94) | 0.72 (0.63–0.84) | ||
|
| ||||||
| Stage II | ||||||
| 2-yr survival, % (95% CI) | 81.2 (79.3–82.9) | 84.0 (82.3–85.7) | 83.9 (82.2–85.5) | 85.9 (84.2–87.4) | ||
| Survival difference, % | 2.8* | −0.1 (−2.1%)† | 2.7* | 2.0 (42.6%)# | 4.7* | |
| P value | .022 | .028 | .0001 | |||
| 3-yr survival, % (95% CI) | 74.5 (72.4–76.5) | 78.1 (76.2–80.0) | 78.6 (76.7–80.5) | 80.3 (78.4–82.1) | ||
| Survival difference, % | 3.6* | 0.5 (8.6%)† | 4.1* | 1.7 (29.3%)# | 5.8* | |
| P value | .011 | .004 | <.0001 | |||
| 5-yr survival, % (95% CI) | 62.7 (60.3–65.1) | 66.7 (64.4–68.9) | 67.3 (65.0–69.6) | 69.3 (67.0–71.5) | ||
| Survival difference, % | 4.0* | 0.6 (9.1%)† | 4.6* | 2.0 (30.3%)# | 6.6* | |
| P value | .019 | .006 | .0001 | |||
| Cox HR (95% CI) | 1 (reference) | 0.86 (0.76–0.96) | 0.84 (0.75–0.94) | 0.77 (0.68–0.87) | ||
|
| ||||||
| Stage III | ||||||
| 2-yr survival, % (95% CI) | 69.0 (66.6–71.3) | 71.2 (68.9–73.4) | 73.5 (71.2–75.6) | 73.0 (70.7–75.1) | ||
| Survival difference, % | 2.2* | 2.3 (57.5%)† | 4.5* | −0.5 (−12.5%)# | 4.0* | |
| P value | .19 | .006 | .016 | |||
| 3-yr survival, % (95% CI) | 60.7 (58.1–63.1) | 62.7 (60.2–65.1) | 63.8 (61.3–66.2) | 64.6 (62.1–67.0) | ||
| Survival difference, % | 2.0* | 1.1 (28.2%)† | 3.1* | 0.8 (20.5%)# | 3.9* | |
| P value | .26 | .076 | .025 | |||
| 5-yr survival, % (95% CI) | 48.9 (46.2–51.5) | 51.7 (49.0–54.3) | 53.2 (50.5–55.8) | 54.0 (51.3–56.6) | ||
| Survival difference, % | 2.8* | 1.5 (29.4%)† | 4.3* | 0.8 (15.7%)# | 5.1* | |
| P value | .14 | .024 | .007 | |||
| Cox HR (95% CI) | 1 (reference) | 0.92 (0.83–1.02) | 0.87 (0.78–0.97) | 0.87 (0.78–0.96) | ||
|
| ||||||
| Stage IV | ||||||
| 2-yr survival, % (95% CI) | 25.4 (22.7–28.2) | 25.8 (23.1–28.7) | 28.9 (26.0–31.8) | 29.8 (26.9–32.8) | ||
| Survival difference, % | 0.4* | 3.1 (70.5%)† | 3.5* | 0.9 (20.5%)# | 4.4* | |
| P value | .83 | .092 | .033 | |||
| 3-yr survival, % (95% CI) | 16.9 (14.5–19.5) | 17.1 (14.7–19.7) | 19.5 (17.0–22.2) | 19.8 (17.2–22.5) | ||
| Survival difference, % | 0.2* | 2.4 (82.8%)† | 2.6* | 0.3 (10.3%)# | 2.9* | |
| P value | .91 | .16 | .13 | |||
| 5-yr survival, % (95% CI) | 9.9 (7.8–12.2) | 9.7 (7.6–12.0) | 10.4 (8.3–12.8) | 12.7 (10.4–15.2) | ||
| Survival difference, % | −0.2* | 0.7 (25.0%)† | 0.5* | 2.3 (82.1%)# | 2.8* | |
| P value | .88 | .75 | .095 | |||
| Cox HR (95% CI) | 1 (reference) | 0.99 (0.90–1.09) | 0.92 (0.84–1.01) | 0.88 (0.79–0.97) | ||
yr: year; CI: confidence interval; HR: hazard ratio; significant effects (P<.05) in bold.
*
Survival differences between black and matched white patients.
#
The absolute difference (percentage) of survival disparity after demographic match explained by presentation.
†
The absolute difference (percentage) of survival disparity after demographic match explained by treatment.